Latest Breaking News On - Translational ocular immunology at tufts medical center - Page 1 : comparemela.com

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved .

OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (NCP)

OKYO Pharma files IND application OK-101 to treat Neuropathic Corneal Pain

OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer, told investors it has filed an Investigational New Drug (IND) application with the US Food.

OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (NCP) Following Announcement of Clinical Trial Agreement with Tufts Medical Center